PHARMACY

Merck, Portola to collaborate to develop stroke treatment

BY Alaric DeArment

WHITEHOUSE STATION, N.J. Two drug companies have announced an exclusive global collaboration and license agreement on an investigational stroke drug.

Merck & Co. and Portola Pharmaceuticals said they would work to develop and commercialize betrixaban, an anticoagulant drug in phase 2 trials as a prevention of stroke in patients with atrial fibrillation.

Merck will pay Portola an initial fee of $50 million for an exclusive worldwide license to betrixaban, and Portola is eligible to receive milestone payments of up to $420 million and royalties on worldwide sales of the drug if it obtains approval. Merck will also assume all development and commercialization costs, including the costs of phase 3 trials. Portola has retained an option to co-fund phase 3 trials in return for additional royalties and to co-promote betrixaban with Merck in the United States.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Rexahn Pharmaceuticals regains compliance with NYSE

BY Allison Cerra

ROCKVILLE, Md. A leader in innovative therapeutics for life-threatening and life-debilitating diseases announced it has regained compliance with NYSE Amex, formerly known as the American Stock Exchange.

Rexahn Pharmaceuticals is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn’s compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain their quality of life.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?
PHARMACY

Study suggests two dietary oils may lower body fat in older women with diabetes

BY Anna Mcgrath

NEW YORK According to a recent study, safflower oil and conjugated linoleic acid may lower body fat in obese postmenopausal women with Type 2 diabetes.

Safflower oil, a common cooking oil, and CLA, a compound naturally found in some meat and dairy products, both consist of primarily polyunsaturated fatty acids, which are considered “good fats” that, when consumed in proper quantities, may promote a variety of health benefits.

All 35 participants were female, younger than 70 years old, obese, postmenopausal and had Type 2 diabetes but did not need to take insulin for the study. Researchers asked that the women consume approximately one and two-thirds teaspoons of either oil daily for a 16-week period. 

The safflower oil supplements reduced trunk fat, lowered blood sugar and increased muscle tissue; while the CLA supplements reduced total body fat and lowered participant’s body mass index. 

“Essentially what we’re trying to understand with nutrition is how dietary approaches can complement Westernized medicine,” said Martha Belury professor of human nutrition at Ohio State University and senior author of the study. “In an ideal world, we’d love it if women like those in our study could use diet, activity and other aspects of a healthy lifestyle to manage their health. But most will probably be on oral medications for the rest of their lives for managing their diabetes and metabolism, which is fine as long as the medications work. We think there’s a chance that nutrition can complement medication and help drugs work even better.” 

Further research is necessary to determine the long-term safety of any kind of supplementation that lowers body fat. Research can be found online and will be published in an upcoming edition of American Journal of Clinical Nutrition.

keyboard_arrow_downCOMMENTS

Leave a Reply

No comments found

TRENDING STORIES

Polls

Which area of the industry do you think Amazon’s entry would shake up the most?